Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study.
BioDrugs
; 38(1): 121-131, 2024 Jan.
Article
in En
| MEDLINE
| ID: mdl-37991693
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Psoriasis
/
Biosimilar Pharmaceuticals
Limits:
Adult
/
Humans
Language:
En
Journal:
BioDrugs
Journal subject:
ALERGIA E IMUNOLOGIA
/
GENETICA MEDICA
/
TERAPEUTICA
/
TERAPIA POR MEDICAMENTOS
Year:
2024
Type:
Article
Affiliation country:
Canada